Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for Monitoring of Drug Response in Primary Cancer Spheroids.

Mittal P, Price ZK, Lokman NA, Ricciardelli C, Oehler MK, Klingler-Hoffmann M, Hoffmann P.

Proteomics. 2019 Aug 31:e1900146. doi: 10.1002/pmic.201900146. [Epub ahead of print] No abstract available.

PMID:
31474002
2.

4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer.

Lokman NA, Price ZK, Hawkins EK, Macpherson AM, Oehler MK, Ricciardelli C.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1187. doi: 10.3390/cancers11081187.

3.

Targeting CDK9 for treatment of colorectal cancer.

Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S.

Mol Oncol. 2019 Aug 9. doi: 10.1002/1878-0261.12559. [Epub ahead of print]

4.

ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients.

Tan IA, Frewin K, Ricciardelli C, Russell DL.

Cell Physiol Biochem. 2019;52(6):1553-1568. doi: 10.33594/000000108.

5.

Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer.

Christensen MV, Høgdall C, Jensen SG, Lokman N, Ricciardelli C, Christensen IJ, Christiansen P, Brask J, Karlsen MA, Nissen TK, Jochumsen KM, Høgdall E.

Anticancer Res. 2019 May;39(5):2475-2482. doi: 10.21873/anticanres.13367.

PMID:
31092442
6.

Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.

Lokman NA, Ho R, Gunasegaran K, Bonner WM, Oehler MK, Ricciardelli C.

J Exp Clin Cancer Res. 2019 Jan 8;38(1):10. doi: 10.1186/s13046-018-1017-7.

7.

S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer.

Noye TM, Lokman NA, Oehler MK, Ricciardelli C.

Int J Mol Sci. 2018 Dec 19;19(12). pii: E4122. doi: 10.3390/ijms19124122. Review.

8.

Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance.

Price ZK, Lokman NA, Ricciardelli C.

Cancers (Basel). 2018 Dec 3;10(12). pii: E482. doi: 10.3390/cancers10120482. Review.

9.

An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Zhang AY, Chiam K, Haupt Y, Fox S, Birch S, Tilley W, Butler LM, Knudsen K, Comstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Ricciardelli C, Böhm M, Henshall S, Delprado W, Stricker P, Horvath LG, Kench JG.

Int J Cancer. 2019 Mar 1;144(5):1151-1159. doi: 10.1002/ijc.31906. Epub 2018 Dec 4.

PMID:
30288742
10.

The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome.

Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, O'Toole SA, Ebrahimie E, Millar EKA, Sakko AJ, Ruiz AI, Vowler SL, Huntsman DG, Birrell SN, Sutherland RL, Palmieri C, Hickey TE, Tilley WD.

Clin Cancer Res. 2018 May 15;24(10):2328-2341. doi: 10.1158/1078-0432.CCR-17-1199. Epub 2018 Mar 7.

11.

Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.

Ricciardelli C, Lokman NA, Sabit I, Gunasegaran K, Bonner WM, Pyragius CE, Macpherson AM, Oehler MK.

Cancer Lett. 2018 May 1;421:51-58. doi: 10.1016/j.canlet.2018.02.006. Epub 2018 Feb 6.

PMID:
29425684
12.

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.

Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.

Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.

13.

WOMEN IN CANCER PROFILE: My pathway to understanding the role of the tumour microenvironment in cancer progression.

Ricciardelli C.

Endocr Relat Cancer. 2016 Nov;23(11):P27-P31. Epub 2016 Aug 16. No abstract available.

PMID:
27530659
14.

Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.

Lokman NA, Pyragius CE, Ruszkiewicz A, Oehler MK, Ricciardelli C.

Transl Res. 2016 May;171:83-95.e1-2. doi: 10.1016/j.trsl.2016.02.002. Epub 2016 Feb 10.

PMID:
26925708
15.

Hypoxia induced HIF-1/HIF-2 activity alters trophoblast transcriptional regulation and promotes invasion.

Highet AR, Khoda SM, Buckberry S, Leemaqz S, Bianco-Miotto T, Harrington E, Ricciardelli C, Roberts CT.

Eur J Cell Biol. 2015 Dec;94(12):589-602. doi: 10.1016/j.ejcb.2015.10.004. Epub 2015 Oct 24.

PMID:
26531845
16.

Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk.

Shawky MS, Ricciardelli C, Lord M, Whitelock J, Ferro V, Britt K, Thompson EW.

J Mammary Gland Biol Neoplasia. 2015 Dec;20(3-4):121-31. Review.

PMID:
26501889
17.

Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.

Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, Ruszkiewicz A, Hoffmann P, Oehler MK.

Clin Exp Metastasis. 2015 Jun;32(5):441-55. doi: 10.1007/s10585-015-9718-1. Epub 2015 Apr 21.

PMID:
25895698
18.

Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling.

Hu F, Dzaye O, Hahn A, Yu Y, Scavetta RJ, Dittmar G, Kaczmarek AK, Dunning KR, Ricciardelli C, Rinnenthal JL, Heppner FL, Lehnardt S, Synowitz M, Wolf SA, Kettenmann H.

Neuro Oncol. 2015 Feb;17(2):200-10. doi: 10.1093/neuonc/nou324. Epub 2014 Dec 1.

19.

Overexpression of piRNA pathway genes in epithelial ovarian cancer.

Lim SL, Ricciardelli C, Oehler MK, Tan IM, Russell D, Grützner F.

PLoS One. 2014 Jun 16;9(6):e99687. doi: 10.1371/journal.pone.0099687. eCollection 2014.

20.

Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.

Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE, Oehler MK.

BMC Cancer. 2013 Oct 14;13:476. doi: 10.1186/1471-2407-13-476.

Supplemental Content

Loading ...
Support Center